DE69311764T2 - Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren - Google Patents

Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren

Info

Publication number
DE69311764T2
DE69311764T2 DE69311764T DE69311764T DE69311764T2 DE 69311764 T2 DE69311764 T2 DE 69311764T2 DE 69311764 T DE69311764 T DE 69311764T DE 69311764 T DE69311764 T DE 69311764T DE 69311764 T2 DE69311764 T2 DE 69311764T2
Authority
DE
Germany
Prior art keywords
sequence
seq
hiv
peptides
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69311764T
Other languages
German (de)
English (en)
Other versions
DE69311764D1 (de
Inventor
Gottfried Himmler
Hermann Katinger
Georg Maiwald
Thomas Muster
Martin Purtscher
Florian Rueker
Franz Steindl
Alexandra Trkola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polymun Scientific Immunbiologische Forschung GmbH
Original Assignee
Polymun Scientific Immunbiologische Forschung GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT98792A external-priority patent/AT403050B/de
Application filed by Polymun Scientific Immunbiologische Forschung GmbH filed Critical Polymun Scientific Immunbiologische Forschung GmbH
Publication of DE69311764D1 publication Critical patent/DE69311764D1/de
Application granted granted Critical
Publication of DE69311764T2 publication Critical patent/DE69311764T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C07K16/1145—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C07K16/4225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69311764T 1992-05-14 1993-05-13 Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren Expired - Lifetime DE69311764T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT98792A AT403050B (de) 1992-05-14 1992-05-14 Peptide, die antikörper binden
US93278792A 1992-08-29 1992-08-29

Publications (2)

Publication Number Publication Date
DE69311764D1 DE69311764D1 (de) 1997-07-31
DE69311764T2 true DE69311764T2 (de) 1998-02-05

Family

ID=25594514

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69311764T Expired - Lifetime DE69311764T2 (de) 1992-05-14 1993-05-13 Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren
DE0570357T Pending DE570357T1 (de) 1992-05-14 1993-05-13 Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE0570357T Pending DE570357T1 (de) 1992-05-14 1993-05-13 Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.

Country Status (6)

Country Link
US (3) US5693752A (Direct)
EP (1) EP0570357B1 (Direct)
JP (1) JP3369246B2 (Direct)
CA (1) CA2096159C (Direct)
DE (2) DE69311764T2 (Direct)
ES (1) ES2053413T3 (Direct)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06506947A (ja) * 1991-04-18 1994-08-04 マウント　シナイ　スクール　オブ　メディスン　オブ　ザ　シティー　ユニバーシティー　オブ　ニューヨーク 抗ウィルスハイブリッド抗体
EP0570357B1 (en) * 1992-05-14 1997-06-25 Polymun Scientific Immunbiologische Forschung GmbH Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates
CN1135237A (zh) * 1993-09-11 1996-11-06 波利门科学生物免疫研究有限公司 诱导针对遗传趋异性hiv-1毒株的中和性抗体的肽
FR2731225B1 (fr) * 1995-03-03 2003-10-31 Pasteur Institut Peptides de glycoproteine transmembranaire d'enveloppe et de proteine de capside du retrovirus humain du type hiv-1 et peptides presentant avec eux une parente immunologique
CA2202408C (fr) * 1994-10-20 2012-03-06 Pierre Charneau Sequences nucleotidiques d'antigenes retroviraux vih-1 groupe (ou sous-groupe) o
GB9424631D0 (en) * 1994-12-06 1995-01-25 Lynxvale Ltd Modulating the immune response
WO1996033219A1 (en) * 1995-04-19 1996-10-24 Polymun Scientific Immunbiologische Forschung Gmbh Monoclonal antibodies against hiv-1 and vaccines made thereof
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US6228128B1 (en) 1997-11-10 2001-05-08 Charlotte Johansen Antimicrobial activity of laccases
US6468544B1 (en) 1998-06-12 2002-10-22 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
ES2653557T3 (es) 1998-06-12 2018-02-07 Icahn School Of Medicine At Mount Sinai Virus de la gripe atenuados con actividad antagonista de interferón alterada para uso como vacunas y productos farmacéuticos
US7090848B1 (en) * 1998-08-04 2006-08-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response
AU762376C (en) * 1998-08-04 2004-10-14 Henry M. Jackson Foundation, The Expression and characterization of HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response
US7115262B1 (en) 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
US6635416B2 (en) * 2000-04-10 2003-10-21 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
CA2473163C (en) 2002-01-17 2011-12-06 Polymun Scientific Immunbiologische Forschung Gmbh Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
US20050003347A1 (en) * 2003-05-06 2005-01-06 Daniel Calarese Domain-exchanged binding molecules, methods of use and methods of production
CN102727880A (zh) 2004-06-01 2012-10-17 西奈山医学院 遗传工程猪流感病毒及其应用
WO2006088740A2 (en) 2005-02-15 2006-08-24 Thymon, L.L.C. Methods and compositions for impairing multiplication of hiv-1
WO2006088481A2 (en) * 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Genetically engineered equine influenza virus and uses thereof
WO2006110831A2 (en) 2005-04-12 2006-10-19 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
AU2007207544A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
WO2008127651A1 (en) * 2007-04-13 2008-10-23 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
HRP20180607T1 (hr) 2011-06-10 2019-04-05 Oregon Health & Science University Glikoproteini i rekombinantni vektori cmv
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
KR20170122786A (ko) 2015-02-26 2017-11-06 베링거잉겔하임베트메디카게엠베하 2가 돼지 인플루엔자 바이러스 백신
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2017093985A1 (en) 2015-12-05 2017-06-08 Centre Hospitalier Universitaire Vaudois Hiv binding agents
WO2020012435A1 (en) 2018-07-13 2020-01-16 Lausanne University Hospital Hiv binding agents
EP3996815A2 (en) 2019-07-15 2022-05-18 Lausanne University Hospital Hiv binding agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007616A1 (en) * 1986-06-12 1987-12-17 Biogen N.V. Peptides involved in the pathogenesis of hiv infection
EP0330359A3 (en) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
EP0362910A3 (en) * 1988-08-27 1991-01-09 Akzo N.V. Synthetic peptides immunochemically reactive with hiv-antibodies
EP0570357B1 (en) * 1992-05-14 1997-06-25 Polymun Scientific Immunbiologische Forschung GmbH Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates

Also Published As

Publication number Publication date
EP0570357A3 (Direct) 1994-04-20
CA2096159A1 (en) 1993-11-15
US5756674A (en) 1998-05-26
US5693752A (en) 1997-12-02
JPH06293797A (ja) 1994-10-21
CA2096159C (en) 2004-07-20
ES2053413T1 (es) 1994-08-01
DE570357T1 (de) 1994-07-28
JP3369246B2 (ja) 2003-01-20
ES2053413T3 (es) 1997-11-16
EP0570357A2 (en) 1993-11-18
EP0570357B1 (en) 1997-06-25
DE69311764D1 (de) 1997-07-31
US5866694A (en) 1999-02-02

Similar Documents

Publication Publication Date Title
DE69311764T2 (de) Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren
Wang et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1.
McLain et al. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus
US6815201B2 (en) HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
DE69428896T2 (de) Hiv immunogene komplexe
Javaherian et al. The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.
AT398080B (de) Immortalisierte zellinie, verfahren zu ihrer herstellung und verfahren zur herstellung von monoklonalen antikörpern sowie diagnoseverfahren und -mittel
Trujillo et al. Molecular mimicry between the human immunodeficiency virus type 1 gp120 V3 loop and human brain proteins
DE69426725T2 (de) Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren
DE69527708T2 (de) Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
EP1465928B1 (en) Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
EP1011707B1 (en) HIV-1 gp120 V1/V2 DOMAIN EPITOPES CAPABLE OF GENERATING NEUTRALIZING ANTIBODIES
Laal et al. Epitopes of HIV-1 glycoproteins recognized by the human immune system
WO1989005821A1 (en) Hiv-related antigens and antibodies
AT403050B (de) Peptide, die antikörper binden
Benjouad et al. Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type‐1 envelope glycoprotein
EP2755687A2 (en) Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
Cranage et al. The simian immunodeficiency virus transmembrane protein is poorly immunogenic in inactivated virus vaccine
Boudet et al. Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice
McLain et al. Claudine Portal, George P. LomonossoffS and Nigel J. Dimmock* zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHG
BOLOGNESI et al. The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type
DD283936A5 (de) Verfahren zur herstellung von peptiden, die in der lage sind immunologisch die neutralisierenden bereiche von hiv proteinen nachzuahmen
CA2099531A1 (en) Monoclonal antibodies to hiv-1 gp120, cell lines producing them, preparations for passive immunotherapy, vaccines containing corresponding epitope structures and process for preparing these antibodies
WO1992022579A1 (en) MIMIC PEPTIDES OF gp120

Legal Events

Date Code Title Description
8364 No opposition during term of opposition